Share |
18 May 2021


Diabetic retinopathy: European researchers looking for support for research-project

amb eyedropLeading European researchers have joined forces under EUROCONDOR - the European Consortium for the Early Treatment of Diabetic Retinopathy - to test the safety and efficacy of the first ever treatment based on eye drops to treat the early stages of diabetic retinopathy, an eye-complication that occurs in people living with diabetes and that can ultimately lead to blindness.

The project, which started in April 2012, is now in its recruitment phase. In total, 11 clinical centres in Europe are taking part in the research project. You can find the full list of project partners here.

EUROCONDOR researchers need your support!

The objective of the EUROCONDOR research project is to find out if eye drops containing neuroprotective drugs (drugs which protect nerves from damage) are an effective treatment in the early stages of diabetic retinopathy.

Currently no treatments are available for treatment of early diabetic retinopathy. It is therefore necessary to develop new treatments that could be applied in the early stages of the disease and prevent progression of this complication of diabetes.

4 clinical centres taking part in EUROCONDOR in particular are looking for support  as part of the research project.

The first two are in Italy - University of Padova, led by Prof Edoardo Midena - and the Università Vita-Salute San Raffaele in Milano, led by Prof Francesco Bandello. The other two are in the United Kingdom: the Moorfields Eye Hospital NHS Foundation Trust, led by Dr Catherine Egan, and the University of Liverpool, led by Prof Simon Harding.

eurocondor logoIf you would like to get more information about the EUROCONDOR project and to get involved, please contact Gaël Bassetto ar This email address is being protected from spambots. You need JavaScript enabled to view it.

The EUROCONDOR project is funded by the European Commission under the 7th Framework Programme - FP7.